BNET Industries
Market Cap:$102.9B
Last Fiscal Year Sales:$32.9B
- Public
- FR
Dow Jones Description
Sanofi-Aventis sees the future - where disease is in the past. Formed by a 2004 merger and headquartered in Paris, France, Sanofi-Aventis (NYSE: SNY (ADR) Euronext Paris: SAN) is the third-largest pharmaceutical maker in the world. The company researches, develops, manufactures, and markets prescription drugs. Its products include Allegra, Aprovel, Eloxatin, Lovenox, Nasacort, Plavix, Taxotere, and Tritace, among others. It has over 100 compounds in development, about 40 of which are in Phase II or III clinical trials. The company has annual revenue of about A28.5 billion and employs about 100,000 people. In March 2006 the company acquired almost 25% of Zentiva NV for approximately A430 million. In 2005 the company sold its interests in Wacker-Chemie.
Number of Employees 97,181
Peer Companies
NAICS Code Drugs and Druggists' Sundries Merchant Wholesalers: 424210
Recent Events
-
Sanofi Recalls Swine Flu Vaccine for Young Children
-
Warner Chilcott Affirms Global Marketing and Collaboration Agreement With Sanofi-Aventis
-
Common heart rhythm problem on the rise in the U.S.
-
Sanofi-Aventis and Alopexx sign collaboration agreement
-
Sanofi-Aventis in research pact with CalTech
-
Generex enters insulin supply deal for Oral-lyn
-
86. Sanofi
-
Sanofi-Aventis SNY Announces Agreement with Intelliject for Novel Epinephrine Auto Injector
-
Early and Often: A Drug Investor's Dream
-
Drugmakers' Differences: Analyst's Toolkit
-
Deutsche Bank Initiates Coverage on Sanofi-Aventis SNY with a Buy
-
Big Pharma Willing to Pay for Biotech Innovation
-
Sanofi-Aventis names Spek global operations head 37 mins ago
-
Sanofi-Aventis Q3 Profit Rises; Lifts FY09 Adj. EPS Growth View; To Buy Laboratoire Oenobiol -...
-
UPDATE 3-Sanofi lifts forecast on swine flu vaccine
-
Sanofi-Aventis and Micromet to Develop New Tumour Antibody
-
Dyax Corp. Q3 2009 Earnings Call Transcript
-
Sanofi-Aventis's New JV Will Provide Entry into Chinas OTC Market
-
Mexico pushing for homegrown swine flu vaccine
News & Analysis
Filter by
finance and sanofi-aventis - All News and Analysis
Sanofi chief set to cede control
Financial Times
- 2009-12-15
Jean-Francois Dehecq, the charismatic chairman of Sanofi-Aventis, who built the French pharmaceutical group through a series of high-profile mergers over the past three decades, is set to hand over control next year to banker and businessman Serge Weinberg.The board will in the coming days discuss the recommendation of its...
Should Sanofi-Aventis Buy Bristol Myers-Squibb?
BNET
- 2008-10-27
Bristol-Myers Squibb CEO James Cornelius said in a recent earnings call that due to its healthy cash position it may be on the prowl for biotech acquisitions. That's ironic because it is looking more like BMS itself could be the company to be acquired, possibly by Sanofi-Aventis. ...
Sanofi strikes back in takeover battle for big Czech drug company
- 2008-06-18
PRAGUE AFP — Czech-based generic drugs giant Zentiva was at the heart of a takeover tussle Wednesday after French group Sanofi-Aventis struck back with an offer countering a bid by local financial concern PPF. PPF, holding a 19.2 percent stake in Zentiva, which has substantial markets in Slovakia, Romania...
French pharmaceutical group Sanofi-Aventis sees net profits rise 9 pct
- 2007-10-31
PARIS AFP — French pharmaceutical group Sanofi-Aventis raised its 2007 performance forecast Wednesday after reporting better-than-expected net earnings in the third quarter. The company said adjusted net profit rose 9.1 percent to 1.853 billion euros (2.7 billion dollars) in the third quarter from the same period last year. ...
Business news in brief
- 2007-02-14
IN THE REGION Drug-design firm raises long-term operating capital Locus Pharmaceuticals Inc., Blue Bell, said it had raised $30.2 million from investors. The computational drug-design and development company said Novartis Bioventures Ltd., Prism Venture Partners and HBM BioVentures Cayman Ltd. led the financing. Other participants included S.R. One...
Sanofi-Aventis slashes share earnings forecast for 2006
- 2006-09-01
PARIS AFP — French pharmaceutical group Sanofi-Aventis has slashed its 2006 earnings per share forecast from 12 percent to just two percent due to competition for its blockbuster blood-thinner Plavix from a generic drug. The revision came a day after a New York court granted the company and its US...
SAP, Sanofi-Aventis expand operations in Hungary
- 2005-07-01
BUDAPEST AFP — SAP, the world's leading maker of business software, and French pharmaceuticals firm Sanofi-Aventis expanded their business operations in Hungary. The German group SAP laid the foundations of a new research and development center in Budapest, its 10th worldwide, which is due to open by year's end,...
Sanofi-Aventis posts 18 pct profit rise in 2004, sees in-line 2005
- 2005-03-01
PARIS AFP — Sanofi-Aventis, the French pharmaceutical firm, posted forecast-beating net profit for 2004 and said it expected earnings this year to be in line with the 2004 performance. Sanofi-Aventis, formed last year in the merger of French firm Sanofi Synthelabo and Franco-German life sciences giant Aventis, said it...
Sanofi-aventis Announces Results of Eloxatin and Cardinal Health to Present at Merrill Lynch Conference.
- 2005-02-04
M2 PRESSWIRE-4 February 2005-FNWU: Sanofi-aventis Announces Results of Eloxatin and Cardinal Health to Present at Merrill Lynch ConferenceC1994-2005 M2 COMMUNICATIONS LTD RDATE:02042005 City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC: FNWU). Sanofi-aventis (NYSE: SNY) announced...
Big Ticket Deals: Some go cold, some heat up
- 2004-11-01
New Jersey held its head high when pharmaceutical giant Sanofi-Aventis of France last month picked the state for its U.S. headquarters. But it might be too early to cheer. Sanofi-Aventis has said that it will locate those offices at Bridgewater Crossing in Bridgewater, where Aventis has its U.S. headquarters and...
- 1
| Volume | 1,912,588 |
| Shares Outstanding | 2.6B |
| Market Cap | 102.9B |
| Year High | 40.28 |
| Year Low | 24.59 |
| Earnings Per Share | 2.21 |
| P/E Ratio | 17.6968 |
| Dividend | 1.0639 |
| Yield | 2.72 |
Industry Transcripts by Seeking Alpha
-
Neogen Corporation F2Q10 (Qtr End11/30/09) Earnings Call Transcript
on Dec 18, 2009about NEOG
-
Schiff Nutrition International, Inc. F2Q10 (Qtr End 11/30/09) Earnings Call Transcript
on Dec 17, 2009about WNI
-
Martek Biosciences Corporation F4Q09 (Qtr End 10/31/09) Earnings Call Transcript
on Dec 16, 2009about MATK
-
Peregrine Pharmaceuticals Inc. F2Q10 (Qtr End 31/10/09) Earnings Call Transcript
on Dec 10, 2009about PPHM
-
Avanir Pharmaceuticals F4Q09 (Qtr End 09/30/2009) Earnings Call Transcript
on Nov 24, 2009about AVNR
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Teva, In Turnabout, Sues to Protect Its Multiple Sclerosis Drug Copaxone 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
Presented by American Express